SPRINT: The Study Nephrologists Might Take With a Grain of Salt

Area of Science:

• Nephrology
• Cardiology
• Clinical Trials

Background:

• Cardiovascular disease (CVD) is a major comorbidity and cause of mortality in patients with chronic kidney disease (CKD).
• Hypertension management is critical for cardiovascular outcomes and renal function but remains controversial in CKD patients.
• The Systolic Blood Pressure Intervention Trial (SPRINT) investigated intensive versus standard systolic blood pressure targets in high cardiovascular risk individuals.

Purpose of the Study:

• To evaluate the impact of an intensive systolic blood pressure goal (120 mm Hg) compared to a standard goal (140 mm Hg) on cardiovascular events in patients with CKD.
• To assess the generalizability of SPRINT findings to the broader CKD population.
• To determine if SPRINT provides sufficient evidence for new hypertension management guidelines in CKD.

Main Methods:

• SPRINT was a randomized controlled trial comparing two systolic blood pressure targets: 120 mm Hg versus 140 mm Hg.
• The trial included a subgroup of patients with chronic kidney disease (CKD).
• CKD data analysis was based on convenience sampling, with approximately 30% of patients in the intensive arm having CKD.

Main Results:

• The intensive blood pressure target of 120 mm Hg significantly reduced combined cardiovascular events across prespecified subgroups, including those with CKD.
• The SPRINT trial demonstrated the benefit of blood pressure control in CKD patients.
• Limitations in CKD patient inclusion and data sampling restrict the external generalizability of SPRINT findings to the entire CKD population.

Conclusions:

• SPRINT highlights the importance of blood pressure control for reducing cardiovascular events in patients with CKD.
• The study suggests that an intensive blood pressure target may be beneficial for CKD patients.
• Further dedicated studies focusing specifically on the CKD population are needed to establish definitive hypertension management guidelines and challenge existing CKD guidelines.